Innoviva

INVA Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$22.99

-1.79% today

52W: $16.52 – $25.15

52W Low: $16.52 Position: 75% 52W High: $25.15

🔗 Compare Brokers

Key Metrics

P/E Ratio

6.97x

Price-to-Earnings

Forward P/E

10.4x

Forward Price/Earnings

P/S Ratio

4.17x

Price-to-Sales

EV/EBITDA

7.53x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.7B

Market Capitalization

Revenue Growth

24.8%

YoY Revenue Growth

Profit Margin

65.92%

Net profit margin

ROE

29.09%

Return on Equity

Beta

0.4

Market sensitivity

Short Interest

12.39%

% of float sold short

Avg. Volume

775,875

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

5 analysts

Avg. Price Target

$33.20

+44.41% upside

Target Range

$18.00 – $46.00

About the Company

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for th

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 159 Exchange: NMS